Variable | C.albicans mean (95%CI) or n (%) | non-C.albicans mean (95%CI) or n (%) | P value | odds ratio (OR) (95%CI) |
---|---|---|---|---|
Demographics | ||||
 gestational age (wks) | 31.7 (27.6, 35.8) | 31.5 (27.7, 36.3) | 0.765 |  |
 birth weight (g) | 1670.0 (962.1,2377.9) | 1417.6 (777.1,2058.1) | 0.128 |  |
 male gender, n (%) | 22 (73.3) | 22 (56.4) | 0.150 | 0.47 (0.17–1.32) |
 admission age | 2.1 (2.0, 6.2) | 1.1 (0.6, 1.6) | 0.138 |  |
Risk factors | ||||
 necrotizing enterocolitis | 5 (16.7) | 12 (30.8) | 0.183 | 2.22 (0.69–7.21) |
 neurodevelopmental impairment | 7 (23.3) | 8 (20.5) | 0.778 | 0.85 (0.27–2.68) |
 maternal underlying diseases | 12 (40.0) | 18 (46.2) | 0.609 | 1.29 (0.50–3.36) |
 assisted reproductive technology | 5 (16.7) | 19 (48.7) | 0.008 | 4.75 (1.51–14.96) |
 vaginal birth | 19 (63.3) | 23 (59.0) | 0.713 | 1.20 (0.45–3.20) |
 fetal membrane rupture (h) | 16.4 (28.4, 61.2) | 26.6 (36.0, 89.2) | 0.459 |  |
 congentital diseases | 13 (43.3) | 24 (61.5) | 0.135 | 2.09 (0.80–5.51) |
 abdominal surgery | 4 (13.3) | 6 (15.4) | 0.811 | 1.18 (0.30–4.63) |
 mechanical ventilation | 14 (46.7) | 29 (74.4) | 0.021 | 3.31 (1.20–9.15) |
 central venous catheter | 14 (46.7) | 27 (69.2) | 0.061 | 2.57 (0.96–6.91) |
 intubation | 10 (33.3) | 21 (53.8) | 0.092 | 2.33 (0.87–6.26) |
 pulmonary active substance use | 7 (23.3) | 9 (23.1) | 0.980 | 0.99 (0.32–3.04) |
 steroids use | 6 (20.0) | 9 (23.1) | 0.759 | 1.20 (0.38–3.84) |
 antacid use | 3 (10.3) | 8 (21.1) | 0.250 | 2.31 (0.56–9.63) |
 total parenteral nutrition | 23 (76.7) | 36 (92.3) | 0.080 | 3.65 (0.86–15.57) |
 hospitalization duration (d) | 43.8 (19.1, 78.5) | 49.1 (26.6, 71.6) | 0.367 |  |
 3rdcephalosporins use | 16 (55.2) | 23 (59.0) | 0.754 | 1.17 (0.44–3.08) |
 carbapenems use | 21 (70.0) | 30 (76.9) | 0.517 | 1.43 (0.49–4.20) |
 vancomycin use | 4 (13.3) | 6 (15.4) | 0.811 | 1.18 (0.30–4.63) |
 multiple antibiotic use | 19 (63.3) | 18 (46.2) | 0.158 | 0.50 (0.19–1.31) |
 antibiotic therapeutic duration (d) | 28.1 (10.0, 46.2) | 38.0 (19.3, 56.7) | 0.033 |  |
 prophylaxis antifungal therapy | 19 (63.3) | 32 (82.1) | 0.084 | 2.65 (0.88–7.99) |
 antifungal therapeutic duration (d) | 7.9 (2.3, 13.5) | 8.8 (2.3, 15.3) | 0.535 |  |
Outcome | ||||
 death | 1 (3.3) | 5 (12.8) | 0.197 | 4.27 (0.47–38.62) |